CING Stock Forecast: Cingulate, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Cingulate, Inc. is $20. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 25 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Cingulate, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (66): The shares have been drifting up relative to others.
Issuance (25): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CING stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CING, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Aug 2026 | Roth Capital | Reiterates | Buy | $10 → $9.00 |
| 20 Aug 2026 | Ascendiant Capital | Maintains | Buy | $52 → $44 |
| 8 June 2026 | Ascendiant Capital | Maintains | Buy | $55 → $52 |
| 26 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 23 Mar 2026 | Roth Capital | Maintains | Buy | — |
| 8 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 19 Nov 2025 | Roth Capital | Maintains | Buy | — |
| 15 Oct 2025 | Roth Capital | Maintains | Buy | — |
| 22 Aug 2025 | Ascendiant Capital | Maintains | Buy | — |
| 27 May 2025 | Ascendiant Capital | Maintains | Buy | — |
| 19 May 2025 | Roth Capital | Maintains | Buy | — |
| 21 Apr 2025 | Ascendiant Capital | Maintains | Buy | — |
| 6 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Jan 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Jan 2025 | Roth MKM | Initiates | Buy | — |
| 20 Nov 2024 | Maxim Group | Upgrade | Buy | — |
| 5 Jan 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 Dec 2023 | Laidlaw & Co. | Downgrade | Hold | — |
| 19 Dec 2023 | Maxim Group | Downgrade | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CING.
This page is one stock. Monday covers all of them.
CING appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CING analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 13.0×
- EV / EBITDA
- —
Cheaper than 6% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −198.7%
- Return on assets
- −66.9%
- Dividend yield
- —
Higher than 8% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cingulate, Inc. has a market value of $67.5M and an enterprise value of $40.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$28.8M.
Diluted earnings per share, trailing twelve months: −$3.62.
Free cash flow in the twelve months to 30 June 2026: −$20.9M.
Cingulate, Inc. employs 14 people.
Data provided by Twelve Data
CING and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CING’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Cingulate, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CING
What is the CING stock price forecast for 2026-2027?
The median 12-month analyst price target for Cingulate, Inc. is $20, with estimates ranging from $8 to $44. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CING stock a buy right now?
Of the 4 analysts covering Cingulate, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cingulate, Inc. 25 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CING?
As at 21 Nov 2026, Cingulate, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (66 of 100).
Will CING stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $20, and Ticker Nerd's factor model ranks Cingulate, Inc. 25 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CING stock forecast for 2030?
No analyst covering Cingulate, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CING are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $44 over the next 12 months.
What does Cingulate, Inc. do?
Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing drug delivery-based therapies for attention deficit/hyperactivity disorder (ADHD) and anxiety. Its Precision Timed Release platform is designed to support once-daily tablet formulations and improve how multi-dose medicines are delivered in routine treatment settings.
About Cingulate, Inc.
Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing drug delivery-based therapies for attention deficit/hyperactivity disorder (ADHD) and anxiety. Its Precision Timed Release platform is designed to support once-daily tablet formulations and improve how multi-dose medicines are delivered in routine treatment settings. The company’s current pipeline includes CTx-1301, a dexmethylphenidate-based candidate for ADHD in children, adolescents, and adults, and CTx-2103, a buspirone-based formulation for anxiety. Cingulate also works on additional stimulant candidates within the same platform to address common psychiatric and behavioral conditions. Based in Kansas City, Kansas, Cingulate serves the biopharmaceutical market through specialized product development centered on chronic conditions that require consistent daily dosing and targeted drug release.
CEO Dr. Shane J. Schaffer Pharm.D. · 14 employees · United States · https://www.cingulate.com